Cleerly news and updates

Every material change AI Health Index has tracked at Cleerly: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Follow this change log by RSS

Free for your reader, newsletter or automation tool. One feed covers the whole index, and every category has its own.

All feeds and terms
Impact
Type
1 entry
Showing changes for Cleerly only.Show the full log

November 2026

C
Cleerly
Nov 7, 2026
HighVerified
Clinical evidence

Cleerly presented primary results of PARAMOUNT, a randomized trial of 530 patients at 21 sites comparing AI-QCT plaque guided care with stress test guided usual care, as Late Breaking Science at AHA 2026. The trial met its composite primary endpoint at 180 days with a win ratio of 2.00 (p<0.0001), and lipid lowering therapy use rose from 31 to 75 percent in the AI-QCT arm versus 32 to 47 percent with usual care. Results are not yet peer reviewed.

Our read

This is randomized outcome level evidence for AI-QCT guided care rather than accuracy data alone, which supports payer coverage arguments and pathway changes away from functional stress testing. Buyers should note the 180 day horizon and the not yet peer reviewed status.

Related axis: Clinical and Operational EvidenceVendor announcementView source

What has changed at Cleerly recently?

The most recent change AI Health Index logged at Cleerly is dated Nov 7, 2026. Cleerly presented primary results of PARAMOUNT, a randomized trial of 530 patients at 21 sites comparing AI-QCT plaque guided care with stress test guided usual care, as Late Breaking Science at AHA 2026.